ProMIS Neurosciences Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.88
- Today's High:
- $2
- Open Price:
- $1.88
- 52W Low:
- $1.5
- 52W High:
- $8.95
- Prev. Close:
- $1.88
- Volume:
- 25196
Company Statistics
- Market Cap.:
- $17.59 million
- Book Value:
- -0.994
- Revenue TTM:
- $7558
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-16087168
- Profit Margin:
- 0%
- Return on Assets TTM:
- -253.99%
- Return on Equity TTM:
- -837.71%
Company Profile
ProMIS Neurosciences Inc. had its IPO on 2007-07-17 under the ticker symbol PMN.
The company operates in the Healthcare sector and Biotechnology industry. ProMIS Neurosciences Inc. has a staff strength of 6 employees.
Stock update
Shares of ProMIS Neurosciences Inc. opened at $1.88 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.88 - $2, and closed at $1.99.
This is a +5.85% increase from the previous day's closing price.
A total volume of 25,196 shares were traded at the close of the day’s session.
In the last one week, shares of ProMIS Neurosciences Inc. have slipped by -2.93%.
ProMIS Neurosciences Inc.'s Key Ratios
ProMIS Neurosciences Inc. has a market cap of $17.59 million, indicating a price to book ratio of 56.7827 and a price to sales ratio of 5168.1934.
In the last 12-months ProMIS Neurosciences Inc.’s revenue was $7558 with a gross profit of $-16087168 and an EBITDA of $-23739800. The EBITDA ratio measures ProMIS Neurosciences Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ProMIS Neurosciences Inc.’s operating margin was 0% while its return on assets stood at -253.99% with a return of equity of -837.71%.
In Q2, ProMIS Neurosciences Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
ProMIS Neurosciences Inc.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.55 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ProMIS Neurosciences Inc.’s profitability.
ProMIS Neurosciences Inc. stock is trading at a EV to sales ratio of 3868.0788 and a EV to EBITDA ratio of -2.6117. Its price to sales ratio in the trailing 12-months stood at 5168.1934.
ProMIS Neurosciences Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.50 million
- Total Liabilities
- $8.74 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
ProMIS Neurosciences Inc. ended 2024 with $1.50 million in total assets and $0 in total liabilities. Its intangible assets were valued at $1.50 million while shareholder equity stood at $-8528292.00.
ProMIS Neurosciences Inc. ended 2024 with $0 in deferred long-term liabilities, $8.74 million in other current liabilities, in common stock, $-87524869.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.22 million and cash and short-term investments were $1.25 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
ProMIS Neurosciences Inc.’s total current assets stands at $1.48 million while long-term investments were $0 and short-term investments were $31825.00. Its net receivables were $46252.00 compared to accounts payable of $7.96 million and inventory worth $175102.00.
In 2024, ProMIS Neurosciences Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, ProMIS Neurosciences Inc. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.99
- 52-Week High
- $8.95
- 52-Week Low
- $1.5
- Analyst Target Price
- $
ProMIS Neurosciences Inc. stock is currently trading at $1.99 per share. It touched a 52-week high of $8.95 and a 52-week low of $8.95. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $2.8 and 200-day moving average was $4.54 The short ratio stood at 0.01 indicating a short percent outstanding of 0%.
Around 1850% of the company’s stock are held by insiders while 220.4% are held by institutions.
Frequently Asked Questions About ProMIS Neurosciences Inc.
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.